Carles Codony

1.9k total citations
29 papers, 1.2k citations indexed

About

Carles Codony is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Carles Codony has authored 29 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Carles Codony's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Mechanisms and Therapy (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Carles Codony is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Mechanisms and Therapy (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Carles Codony collaborates with scholars based in Spain, Italy and United States. Carles Codony's co-authors include Andrew J. Hamilton, Gurman S. Pall, John Byrne, Rafael Rosell, Niki Karachaliou, Jordi Codony‐Servat, Fausto G. Hegardt, Guillermina Asins, Dolors Serra and M.A. Bach and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

Carles Codony

27 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carles Codony Spain 13 873 353 213 169 125 29 1.2k
Huibo Wang China 20 834 1.0× 466 1.3× 214 1.0× 89 0.5× 90 0.7× 32 1.1k
Barbara Frederick United States 19 889 1.0× 395 1.1× 402 1.9× 231 1.4× 65 0.5× 33 1.4k
Mark Sun Canada 13 839 1.0× 240 0.7× 134 0.6× 63 0.4× 106 0.8× 16 1.1k
Swetansu Pattnaik United States 9 662 0.8× 259 0.7× 401 1.9× 152 0.9× 42 0.3× 12 979
Haixin Lei China 21 963 1.1× 405 1.1× 239 1.1× 104 0.6× 81 0.6× 28 1.3k
Julie Bianchi United Kingdom 14 1.4k 1.6× 401 1.1× 641 3.0× 162 1.0× 63 0.5× 22 1.8k
Víctor M. Villalobos United States 23 821 0.9× 143 0.4× 423 2.0× 374 2.2× 94 0.8× 70 1.5k
Claudia Schneider United Kingdom 23 2.0k 2.3× 142 0.4× 247 1.2× 77 0.5× 96 0.8× 36 2.2k
Sunita Shankar United States 11 1.6k 1.8× 873 2.5× 317 1.5× 268 1.6× 65 0.5× 21 2.0k
Jiang Ren China 21 772 0.9× 289 0.8× 499 2.3× 130 0.8× 52 0.4× 34 1.3k

Countries citing papers authored by Carles Codony

Since Specialization
Citations

This map shows the geographic impact of Carles Codony's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carles Codony with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carles Codony more than expected).

Fields of papers citing papers by Carles Codony

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carles Codony. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carles Codony. The network helps show where Carles Codony may publish in the future.

Co-authorship network of co-authors of Carles Codony

This figure shows the co-authorship network connecting the top 25 collaborators of Carles Codony. A scholar is included among the top collaborators of Carles Codony based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carles Codony. Carles Codony is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Castillo, J.J. Soto, Rafael Moreno, Carles Codony, et al.. (2023). SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy. International Journal of Molecular Sciences. 24(13). 11143–11143. 4 indexed citations
2.
Attili, Ilaria, Laura Bonanno, Niki Karachaliou, et al.. (2020). SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Translational Lung Cancer Research. 9(5). 1810–1821. 11 indexed citations
3.
Bracht, Jillian Wilhelmina Paulina, Niki Karachaliou, Jordi Berenguer, et al.. (2019). PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer. Journal of Cancer Metastasis and Treatment. 2019. 12 indexed citations
4.
Bertrán-Alamillo, Jordi, Valérie Cattan, Marie Schoumacher, et al.. (2019). AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nature Communications. 10(1). 1812–1812. 88 indexed citations
5.
Bracht, Jillian Wilhelmina Paulina, Niki Karachaliou, Jordi Berenguer, et al.. (2019). Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC). International Journal of Biological Sciences. 15(12). 2607–2614. 28 indexed citations
6.
Ito, Masaoki, Carles Codony, Niki Karachaliou, & Rafael Rosell. (2019). Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer. Translational Lung Cancer Research. 8(5). 667–673. 11 indexed citations
7.
Codony‐Servat, Jordi, Carles Codony, Andrés F. Cardona, et al.. (2019). Cancer Stem Cell Biomarkers in EGFR-Mutation–Positive Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 20(3). 167–177. 39 indexed citations
8.
Codony‐Servat, Jordi, Carles Codony, Santiago Viteri, et al.. (2019). Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models. Annals of Oncology. 30. v10–v11. 2 indexed citations
9.
Codony‐Servat, Jordi, Santiago Viteri, Carles Codony, et al.. (2019). Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines. Translational Lung Cancer Research. 8(4). 340–351. 14 indexed citations
10.
Ito, Masaoki, Carles Codony, Jordi Codony‐Servat, et al.. (2018). 25P A non-pathway-specific approach in EGFR and KRAS mutant or squamous cell histology non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 13(4). S13–S14.
11.
Jacobsen, Kirstine, Jordi Bertrán-Alamillo, Miguel Ángel Molina‐Vila, et al.. (2017). Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature Communications. 8(1). 410–410. 118 indexed citations
12.
Rosell, Rafael, Imane Chaib, Niki Karachaliou, et al.. (2017). OA10.03 YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer. Journal of Thoracic Oncology. 12(1). S281–S282. 1 indexed citations
13.
Verlicchi, Alberto, Niki Karachaliou, Chiara Lazzari, et al.. (2017). P3.01-038 STAT3 and Src-YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma. Journal of Thoracic Oncology. 12(1). S1143–S1143.
14.
Verlicchi, Alberto, Niki Karachaliou, Chiara Lazzari, et al.. (2016). 72P Differential expression profile of lung squamous cell carcinoma (LSCC) cell lines as a mean to predict drug interaction effects. Journal of Thoracic Oncology. 11(4). S85–S86. 1 indexed citations
15.
Baptista, Maria João, Ana Muntañola, Pau Abrisqueta, et al.. (2012). Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clinical Cancer Research. 18(21). 5924–5933. 4 indexed citations
16.
Plass, Mireya, Carles Codony, Pedro G. Ferreira, Josep Vilardell, & Eduardo Eyras. (2012). RNA secondary structure mediates alternative 3′ss selection in Saccharomyces cerevisiae. RNA. 18(6). 1103–1115. 34 indexed citations
17.
Codony, Carles, Marta Crespo, Pau Abrisqueta, Emili Montserrat, & Francesc Bosch. (2009). Gene expression profiling in chronic lymphocytic leukaemia. Best Practice & Research Clinical Haematology. 22(2). 211–222. 17 indexed citations
18.
Pall, Gurman S., et al.. (2007). Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot. Nucleic Acids Research. 35(8). e60–e60. 386 indexed citations
19.
Hegardt, Fausto G., M.A. Bach, Guillermina Asins, et al.. (2001). Post-transcriptional regulation of rat carnitine octanoyltransferase. Biochemical Society Transactions. 29(2). 316–316. 1 indexed citations
20.
Cicarelli, Regina Maria Barretto, et al.. (1998). A Second-Step Splicing Activity Is Conserved from Yeast to Human. Biochemical and Biophysical Research Communications. 247(2). 204–206. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Huibo Wang Breakdown of academic impact, for papers by Barbara Frederick Breakdown of academic impact, for papers by Mark Sun Breakdown of academic impact, for papers by Swetansu Pattnaik Breakdown of academic impact, for papers by Haixin Lei Breakdown of academic impact, for papers by Julie Bianchi Breakdown of academic impact, for papers by Víctor M. Villalobos Breakdown of academic impact, for papers by Claudia Schneider Breakdown of academic impact, for papers by Sunita Shankar Breakdown of academic impact, for papers by Jiang Ren
Rankless by CCL
2026